Replies to post #49396 on Biotech Values

[DewDiligence]

>Amylin has inked deals with Alkermes and Nastech (nasal spray formulation)<

The NSTK collaboration appears to be all but forgotten. Perhaps AMLN is now sufficiently satisfied with LAR that they no longer need the intranasal idea as a backup.

>at 33 cents its almost lights out for that [ConjuChem] technology<

I’ve never been a fan of ConjuChem. In fact, I criticized their clinical data on this board three years ago when others raved about it. However, even a company whose share price is 33 cents can wreak havoc at the USPTO. I would not be so quick to dismiss the patent interference as a non-issue just because the company is in dire straits financially.